Atara Biotherapeutics (ATRA)
(Delayed Data from NSDQ)
$0.69 USD
-0.01 (-1.40%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $0.69 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth C Momentum F VGM
Cash flow Statements
Fiscal Year End for Atara Biotherapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -276.13 | -228.30 | -340.14 | -306.62 | -290.98 |
Depreciation/Amortization & Depletion | 5.62 | 6.68 | 11.11 | 9.16 | 5.74 |
Net Change from Assets/Liabilities | 15.34 | -61.47 | 52.58 | 63.69 | -4.15 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 62.19 | 12.66 | 55.92 | 53.02 | 53.76 |
Net Cash From Operating Activities | -192.98 | -270.43 | -220.52 | -180.76 | -235.63 |
Property & Equipment | -1.20 | -4.19 | -10.58 | -4.51 | -5.57 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 125.06 | 112.38 | 32.84 | -116.22 | 66.03 |
Other Investing Activities | 0.00 | 94.77 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 123.87 | 202.96 | 22.26 | -120.73 | 60.46 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 3.06 | 23.81 | 105.46 | 429.65 | 195.97 |
Issuance (Repayment) of Debt | -0.95 | 30.09 | -0.25 | -0.39 | -0.49 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -0.11 | -0.82 | -1.26 | -1.69 | -6.70 |
Net Cash from Financing Activities | 2.01 | 53.08 | 103.94 | 427.57 | 188.79 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -67.10 | -14.39 | -94.32 | 126.09 | 13.62 |
Cash at Beginning of Period | 93.09 | 107.48 | 201.80 | 75.71 | 62.09 |
Cash at End of Period | 25.99 | 93.09 | 107.48 | 201.80 | 75.71 |
Diluted Net EPS | -2.61 | -2.24 | -3.63 | -4.15 | -5.67 |
Fiscal Year End for Atara Biotherapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | NA | -276.13 | -215.68 | -145.88 | -74.77 |
Depreciation/Amortization & Depletion | NA | 5.62 | 2.30 | 1.31 | 0.86 |
Net Change from Assets/Liabilities | NA | 15.34 | 22.62 | 20.65 | 19.55 |
Net Cash from Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | NA | 62.19 | 48.18 | 32.70 | 15.93 |
Net Cash From Operating Activities | NA | -192.98 | -142.57 | -91.23 | -38.43 |
Property & Equipment | NA | -1.20 | -1.15 | -0.90 | -0.40 |
Acquisition/ Disposition of Subsidiaries | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | NA | 125.06 | 115.08 | 44.37 | -5.61 |
Other Investing Activities | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | NA | 123.87 | 113.92 | 43.48 | -6.01 |
Uses of Funds
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | NA | 3.06 | 1.34 | 1.34 | 0.64 |
Issuance (Repayment) of Debt | NA | -0.95 | -0.73 | -0.52 | -0.31 |
Increase (Decrease) Short-Term Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | NA | -0.11 | -0.11 | -0.11 | -0.09 |
Net Cash from Financing Activities | NA | 2.01 | 0.50 | 0.71 | 0.24 |
Effect of Exchange Rate Changes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | NA | -67.10 | -28.15 | -47.04 | -44.20 |
Cash at Beginning of Period | NA | 93.09 | 93.09 | 93.09 | 93.09 |
Cash at End of Period | NA | 25.99 | 64.94 | 46.04 | 48.89 |
Diluted Net EPS | NA | -0.55 | -0.66 | -0.68 | -0.72 |